Table 1 Characteristics of the studies included in the meta-analysis
Reference | Country | Study design | Pathology | Sample size | Number of OTT | Mean age at OTC (years) | Mean age at OTT (years, first time) | Transplantation sites | Quality score |
|---|---|---|---|---|---|---|---|---|---|
Marine Leflon et al. 2022 | France | Cohort study | Lymphoma:8; Breast cancer:1 | 9 | 9 | 26.2 ± 3.9 | 32.5 ± 3.88 | O + P:8; P:1 | 6 |
R. Imbert et al. 2014 | Belgium | Cohort study | HL:2; Breast cancer:1; Colorectal cancer:1; Sickle cell disease:1; NHD:1 | 6 | 7 | 25.1 ± 6.9 | 30.1 ± 5.8 | O + P + SC:1; O + SC:4; O + P:2 | 6 |
 C. Poirot et al. 2019 | France | Cohort study | Borderline tumour:3; NHD:9; Cervix cancer:1; Pseudomyxomal peritonei:1; Shwachman–Diamond syndrome:1; Sickle cell disease:1; β Thalassemia:1; HL:13; Ewing sarcoma:1 | 31 | 38 | 26.2 ± 5.8 | 33.5 ± 4.8 | O + P:34; HT:4 | 6 |
M. Vatel et al. 2021 | France | Cohort study | HL:5; NHD:2; Sickle cell disease:1; Pseudo-myxoma:1; Invasive cervical carcinoma:1; Ovarian borderline tumor:1; | 11 | 16 | 26.3 ± 6.0 | 32.6 ± 5.4 | P:14; HT:2 | 6 |
Matthia W et al. 2017 | Germany | Cohort study | hematologic neoplasia:17; breast carcinoma:10; germ cell or borderline ovarian tumor:4; anal cancer:3; premature ovarian failure:2; ovarian cancer:1; cervical cancer:1 | 38 | 39 | NA | 34.8 (range 27–44 years). | P:39 | 5 |
Ina Marie Dueholm Hjorth et al. 2020 | Denmark | Cohort study | breast cance:14; hematologic malignancies:8; other malignancies:5; benign disease:1 | 28 | 36 | 29.8 ± 5.2 | 34.0 ± 5.1 | P:18; O:10; P + O:8 | 6 |
Jana Liebenthron et al. 2019 | Germany | Cohort study | Breast cancer:13; HL:8; NHD:5; Sarcoma:1; Gynecological cancer:1; Other types of malignancies:1; Lupus erythematosus:1 | 30 | 30 | 31.1 ± 5.0 | 34.8 ± 4.3 | P:27; O + P:3 | 6 |
Ellen J. Hoekman et al. 2019 | Netherlands | Cohort study | Breast cancer:3; HL:2; NHD:1; Ewing’s sarcoma:1 | 7 | 9 | 27.0 ± 4.7 | 33.4 ± 5.8 | O:8; O + P:1 | 6 |
Debra Gook et al. 2021 | Australia | Cohort study | due to a cancer diagnosis:14 | 17 | 25 | 27.4 | 33.4 | Â A:9; O:9: P:7 | 6 |
Tryde Schmidt et al. 2011 | Denmark | Cohort study | NHD:2; Hodgkin:4; Ewing’s sarcoma:1; Breast cancer:1; paroxysmal nocturnal hemoglobinuri:1; Aplastic anemia:1; Cervical cancer:1; hemolytic urinary syndrome:1 | 12 | 17 | NA | 28.4 ± 4.9 | O:8; O + A:5; O + A + P:2; O + P:1; P:1 | 6 |
Tine Greve et al. 2012 | Demark | Cohort study | NHD:2; HL:4; Ewing sarcoma:1; Breast cancer:3; PNH:1; Aplastic anemia:1 | 12 | 19 | 29.3 ± 5.3 | 31.5 ± 5.4 | O:11; O + A:5; O + A + P:2; O + P:1 | 6 |
Genia Rozen et al. 2021 | Australia | Cohort study | oncological (81%); medical (19%) indications | 11 | 12 | 27.3 ± 6.6 | 34.7 ± 5.8 |  A:2; P:5; O:2; A + O:1; O + P:1; A + P:1 | 6 |